Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391066
Status:
TERMINATED
Last Update Posted:
2015-10-02
First Post:
2006-10-19
Brief Title:
Lumiliximab With Fludarabine Cyclophosphamide and Rituximab FCR Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia CLL
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Randomized Open Label Multicenter Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine Cyclophosphamide and Rituximab Versus Fludarabine Cyclophosphamide and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia
Status:
TERMINATED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LUCID
Brief Summary:
This is a randomized 11 open-label multicenter active-controlled study in patients with previously treated CD23 and CD20 relapsed CLL Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None